奥妥珠单抗治疗免疫性血栓性血小板减少性紫癜:一例病例报告及文献复习
回顾性分析哈尔滨医科大学附属第一医院血液科收治的1例66岁女性iTTP患者,因严重输液反应停用利妥昔单抗后改用奥妥珠单抗(1000 mg每周1次×2周)获得18个月完全缓解,未发生药物相关不良事件,结论认为对利妥昔单抗不耐受的iTTP患者奥妥珠单抗是安全有效的替代治疗选择。
要点
- 利妥昔单抗不耐受的iTTP患者,奥妥珠单抗(1000 mg每周1次×2周)获得18个月完全缓解。
- 治疗期间未发生与奥妥珠单抗相关的不良事件。
- 作者结论认为奥妥珠单抗是利妥昔单抗不耐受iTTP患者安全有效的替代治疗选择。
核心结论
- 对于利妥昔单抗不耐受的iTTP患者,奥妥珠单抗是安全、有效的替代治疗选择。
研究设计与样本
- 回顾性分析哈尔滨医科大学附属第一医院血液科收治的1例iTTP患者的诊疗经过并进行文献复习。
主要发现
- 患者女,66岁,因发现血小板减少1 d入院,入院查体皮肤、巩膜黄染,意识清但计算力下降。
- 辅助检查:血小板7×10(9)/L,外周血涂片破碎红细胞4%,谷丙转氨酶55.2 U/L,谷草转氨酶117.5 U/L,总胆红素142.7 μmol/L,直接胆红素64.6 μmol/L,间接胆红素78.1 μmol/L,乳酸脱氢酶2362 U/L,肌酐260.7 μmol/L,ADAMTS13活性2.7%且抑制物阳性(1.12 BU),符合iTTP诊断标准。
- 接受血浆置换及甲泼尼龙治疗后症状及辅助检查未好转,利妥昔单抗因严重输液反应停用,改用奥妥珠单抗(1000 mg每周1次×2周)获得18个月完全缓解,未发生与奥妥珠单抗相关的不良事件。
临床怎么用
- 作者结论认为,对于利妥昔单抗不耐受的iTTP患者,奥妥珠单抗是安全、有效的替代治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the safety and efficacy of Obinutuzumab in the treatment of immune thrombotic thrombocytopenic purpura. Methods: Data from a case of immune thrombotic thrombocytopenic purpura (iTTP) admitted to the Department of haematology of the First Affiliated Hospital of Harbin Medical University were evaluated retrospectively and a literature review was performed. Results: A 66-year-old female patient was admitted to our hospital for thrombocytopenia. On admission, physical examination showed that yellow skin and sclera. The patient was fully conscious but had a decreasing ability to calculate. Laboratory examination revealed a platelet count of 7×10(9)/L; liver function: alanine aminotransferase 55.2 U/L, azelaic aminotransferase 117.5 U/L; total bilirubin 142.7 μmol/L, direct bilirubin 64.6 μmol/L, indirect bilirubin 78.1 μmol/L; lactate dehydrogenase: 2362 U/L; creatinine: 260.7 μmol/L; peripheral blood smear showed 4% fragmented erythrocytes; ADAMTS13 activity 2.7% and positive inhibitor (1.12 BU). The patient is treated with plasma exchange and glucocorticoids, but the patient's symptoms worsened. Rituximab was permanently discontinued for severe infusion reactions. Treatment with Obinutuzumab (1000 mg, qw×2 w) and she achieved a complete remission for 18 months. The treatment was well tolerated with no adverse events related to Obinutuzumab. Conclusion: For iTTP patients with rituximab intolerance, obinutuzumab is a safe and effective alternative treatment option. 目的: 探讨奥妥珠单抗治疗免疫性血栓性血小板减少性紫癜(iTTP)的安全性和有效性。 方法: 回顾哈尔滨医科大学附属第一院血液科收治的1例iTTP患者的诊疗经过并进行文献复习。 结果: 患者,女,66岁,因发现血小板减少1 d入院,入院查体皮肤、巩膜黄染,意识清,但计算力下降。辅助检查:PLT 7×10(9)/L;外周血涂片破碎红细胞4%;肝功:谷丙转氨酶55.2 U/L,谷草转氨酶117.5 U/L;总胆红素142.7 μmol/L,直接胆红素64.6 μmol/L,间接胆红素78.1 μmol/L;乳酸脱氢酶2362 U/L;肌酐260.7 μmol/L;血管性血友病因子裂解蛋白酶(ADAMTS13)活性2.7%且抑制物阳性(1.12 BU),符合iTTP诊断标准。接受血浆置换及甲泼尼龙治疗后症状及辅助检查未好转,利妥昔单抗因严重的输液反应停用,改用奥妥珠单抗(1000 mg每周1次×2周)获得18个月的疾病缓解,未发生严重不良事件。 结论: 对于利妥昔单抗不耐受的iTTP患者,奥妥珠单抗是安全、有效的替代治疗选择。.
引用
- Chen XT, Zhao YQ, Li Q, et al. [Immune thrombotic thrombocytopenic purpura treated with Obinutuzumab: a case report and literature review]. Zhonghua Xue Ye Xue Za Zhi. 2024. PMID: 40032339. doi:10.3760/cma.j.cn121090-20241123-00474
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。